Advertisement

Predicted Effects of Treatment for HCV Infection Vary Among European Countries

      Background & Aims

      The dynamics of hepatitis C virus (HCV) infection, as well as screening practices and access to therapy, vary among European countries. It is important to determine the magnitude of the effects of such differences on incidence and mortality of infection. We compared the dynamics of infection and screening and treatment practices among Belgium, France, Germany, Italy, Spain, and the United Kingdom. We also assessed the effects of treatment with pegylated interferon and additional effects of triple therapy with protease inhibitors.

      Methods

      We created a country-specific Markov model of HCV progression based on published epidemiologic data (on HCV prevalence, screening, genotype, alcohol consumption among patients, and treatments) and reports of competitive and hepatocellular carcinoma mortality for the 6 countries. The model was used to predict the incidence of HCV-related cirrhosis and its mortality until 2021 for each country.

      Results

      From 2002 to 2011, antiviral therapy reduced the cumulative incidence of cirrhosis by 7.1% and deaths by 3.4% overall. Reductions in incidence and mortality values ranged from 4.0% and 1.9%, respectively, in Italy to 16.3% and 9.0%, respectively, in France. From 2012 to 2021, antiviral treatment of patients with HCV genotype 1 infection that includes protease inhibitor–based triple therapy will reduce the cumulative incidence of cirrhosis by 17.7% and mortality by 9.7% overall. The smallest reduction is predicted for Italy (incidence reduced by 10.1% and mortality by 5.4%) and the highest is for France (reductions of 34.3% and 20.7%, respectively).

      Conclusions

      Although HCV infection is treated with the same therapies in different countries, the effects of the therapies on morbidity and mortality vary significantly. In addition to common guidelines that are based on virologic response-guided therapy, there is a need for public health policies based on population-guided therapy.

      Keywords

      Abbreviations used in this paper:

      CI (confidence interval), G (genotype), PEG-IFN (pegylated interferon), PI (protease inhibitor), RBV (ribavirin), SVR (sustained virologic response)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Armstrong G.L.
        • Alter M.J.
        • McQuillan G.M.
        • et al.
        The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States.
        Hepatology. 2000; 31: 777-782
        • Deuffic S.
        • Buffat L.
        • Poynard T.
        • et al.
        Modeling the hepatitis C virus epidemic in France.
        Hepatology. 1999; 29: 1596-1601
        • Davis G.L.
        • Albright J.E.
        • Cook S.F.
        • et al.
        Projecting future complications of chronic hepatitis C in the United States.
        Liver Tranpl. 2003; 9: 331-338
        • Davis G.L.
        • Alter M.J.
        • El-Serag H.
        • et al.
        Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.
        Gastroenterology. 2010; 138: 513-521
        • Deuffic-Burban S.
        • Deltenre P.
        • Louvet A.
        • et al.
        Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France.
        J Hepatol. 2008; 49: 175-183
        • Wong J.
        • McQuillan G.M.
        • McHutchinson J.G.
        • et al.
        Estimating future hepatitis C morbidity, mortality, and costs in the United States.
        Am J Public Health. 2000; 90: 1562-1569
        • Sypsa V.
        • Touloumi G.
        • Papatheodoridis G.V.
        • et al.
        Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments.
        J Viral Hepat. 2005; 12: 543-550
        • Fried M.W.
        • Shiffman M.L.
        • Reddy K.R.
        • et al.
        Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
        N Engl J Med. 2002; 347: 975-982
        • Manns M.
        • McHutchinson J.G.
        • Gordon S.
        • et al.
        Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
        Lancet. 2001; 358: 958-965
        • Hezode C.
        • Forestier N.
        • Dusheiko G.
        • et al.
        Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
        N Engl J Med. 2009; 360: 1839-1850
        • Jacobson I.M.
        • McHutchison J.G.
        • Dusheiko G.
        • et al.
        Telaprevir for previously untreated chronic hepatitis C virus infection.
        N Engl J Med. 2011; 364: 2405-2416
        • Kwo P.Y.
        • Lawitz E.J.
        • McCone J.
        • et al.
        Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
        Lancet. 2010; 376: 705-716
        • McHutchison J.G.
        • Everson G.T.
        • Gordon S.C.
        • et al.
        Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
        N Engl J Med. 2009; 360: 1827-1838
        • Poordad F.
        • McCone Jr, J.
        • Bacon B.R.
        • et al.
        Boceprevir for untreated chronic HCV genotype 1 infection.
        N Engl J Med. 2011; 364: 1195-1206
        • Sherman K.E.
        • Flamm S.L.
        • Afdhal N.H.
        • et al.
        Response-guided telaprevir combination treatment for hepatitis C virus infection.
        N Engl J Med. 2011; 365: 1014-1024
        • Bacon B.R.
        • Gordon S.C.
        • Lawitz E.
        • et al.
        Boceprevir for previously treated chronic HCV genotype 1 infection.
        N Engl J Med. 2011; 364: 1207-1217
        • McHutchison J.G.
        • Manns M.P.
        • Muir A.J.
        • et al.
        Telaprevir for previously treated chronic HCV infection.
        N Engl J Med. 2010; 362: 1292-1303
        • Zeuzem S.
        • Andreone P.
        • Pol S.
        • et al.
        Telaprevir for retreatment of HCV infection.
        N Engl J Med. 2011; 364: 2417-2428
        • Muhlberger N.
        • Schwarzer R.
        • Lettmeier B.
        • et al.
        HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality.
        BMC Public Health. 2009; 9: 34
        • Lettmeier B.
        • Muhlberger N.
        • Schwarzer R.
        • et al.
        Market uptake of new antiviral drugs for the treatment of hepatitis C.
        J Hepatol. 2008; 49: 528-536
        • Mariano A.
        • Caserta C.
        • Pendino G.M.
        • et al.
        Antiviral treatment for hepatitis C virus infection: effectiveness at general population level in a highly endemic area.
        Dig Liver Dis. 2009; 41: 509-515
        • Centers for Disease Control and Prevention
        Disease burden from viral hepatitis A, B, and C in the United States.
        • Sweeting M.J.
        • Hope V.D.
        • Hickman M.
        • et al.
        Hepatitis C infection among injecting drug users in England and Wales (1992–2006): there and back again?.
        Am J Epidemiol. 2009; 170: 352-360
        • Gerard C.
        • Delwaide J.
        • Vaira D.
        • et al.
        Evolution over a 10 year period of the epidemiological profile of 1,726 newly diagnosed HCV patients in Belgium.
        J Med Virol. 2005; 76: 503-510
        • Poynard T.
        • Bedossa P.
        • Opolon P.
        • OBSVIRC, METAVIR, CLINIVIR, DOSVIRC Groups
        Natural history of liver fibrosis progression in patients with chronic hepatitis C.
        Lancet. 1997; 349: 825-832
        • Roudot-Thoraval F.
        • Bastie A.
        • Pawlotsky J.M.
        • et al.
        Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients.
        Hepatology. 1997; 26: 485-490
        • Martinot-Peignoux M.
        • Roudot-Thoraval F.
        • Mendel I.
        • et al.
        Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy.
        The GEMHEP. J Viral Hepat. 1999; 6: 435-443
        • Payan C.
        • Roudot-Thoraval F.
        • Marcellin P.
        • et al.
        Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study.
        J Viral Hepat. 2005; 12: 405-413
        • Huppe D.
        • Zehnter E.
        • Mauss S.
        • et al.
        Epidemiology of chronic hepatitis C in Germany—an analysis of 10,326 patients in hepatitis centres and outpatient unit [in German].
        Z Gastroenterol. 2008; 46: 34-44
        • Mariano A.
        • Scalia Tomba G.
        • Tosti M.E.
        • et al.
        Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy.
        Scand J Infect Dis. 2009; 41: 689-699
        • Matera G.
        • Lamberti A.
        • Quirino A.
        • et al.
        Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy.
        Diagn Microbiol Infect Dis. 2002; 42: 169-173
        • Echevarria J.M.
        • Leon P.
        • Pozo F.
        • et al.
        Follow-up of the prevalence of hepatitis C virus genotypes in Spain during a nine-year period (1996-2004).
        Enferm Infecc Microbiol Clin. 2006; 24: 20-25
        • Serra M.A.
        • Rodriguez F.
        • del Olmo J.A.
        • et al.
        Influence of age and date of infection on distribution of hepatitis C virus genotypes and fibrosis stage.
        J Viral Hepat. 2003; 10: 183-188
      1. Hepatitis C in the UK 2009.
        Health Protection Agency Centre for Infections, London, England2009
        • Hutchinson S.J.
        • Roy K.M.
        • Wadd S.
        • et al.
        Hepatitis C virus infection in Scotland: epidemiological review and public health challenges.
        Scott Med J. 2006; 51: 8-15
        • Mohsen A.H.
        • Trent HCV Study Group
        The epidemiology of hepatitis C in a UK health regional population of 5.12 million.
        Gut. 2001; 48: 707-713
        • Cornberg M.
        • Razavi H.A.
        • Alberti A.
        • et al.
        A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.
        Liver Int. 2011; 31: 30-60
        • Meffre C.
        • Le Strat Y.
        • Delarocque-Astagneau E.
        • et al.
        Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors.
        J Med Virol. 2010; 82: 546-555
        • Carsauw H.
        • Adler M.
        • Goubau P.
        • et al.
        Investigations following the use of inactive batch of Cidex solution in Belgian hospitals.
        Acta Gastroenterol Belg. 2003; 66: D35
        • Zehnter E.
        • Mauss S.
        • John C.
        • et al.
        Efficacy of peginterferon alfa-2a (40KD) and ribavirin in patients with chronic hepatitis C in Germany—a contribution to health care (abstr).
        Hepatology. 2005; 42: 683A
        • The Hepatitis C Trust
        The UK vs. Europe: Losing the fight against hepatitis C.
        University of Southampton, London, England2006
        • Varela M.
        • Reig M.
        • de la Mata M.
        • et al.
        Treatment approach of hepatocellular carcinoma in Spain.
        Med Clin (Barc). 2010; 134: 569-576
        • Costella A.
        Health Protection Agency United Kingdom. Hepatitis C in the UK 2008. The Health Protection Agency Annual Report.
        Health Protection Agency Centre for Infections, London, England2008
        • Goldberg D.
        • Brown G.
        • Hutchinson S.
        • et al.
        Hepatitis C action plan for Scotland: phase II (May 2008-March 2011).
        Euro Surveill. 2008; 13
        • McHutchison J.G.
        • Gordon S.C.
        • Schiff E.R.
        • et al.
        Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.
        N Engl J Med. 1998; 339: 1485-1492
        • Pariente A.
        • Lahmek P.
        • Duprat C.
        • et al.
        Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life': a plea in favor of independent postmarketing evaluations.
        Eur J Gastroenterol Hepatol. 2010; 22: 1297-1302
        • Schalm S.W.
        • Weiland O.
        • Hansen B.E.
        • et al.
        Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials.
        Gastroenterology. 1999; 117: 408-413
        • McHutchison J.G.
        • Lawitz E.J.
        • Shiffman M.L.
        • et al.
        Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
        N Engl J Med. 2009; 361: 580-593
        • Pol S.
        • Ghalib R.H.
        • Rustgi V.K.
        • et al.
        First report of SVR12 for a NS5A replication complex inhibitor, BMS-790052 in combination with PEG-IFNα-2a and RBV: Phase 2a trial in treatment-naive HCV-genotype 1 subjects.
        J Hepatol. 2011; 54: S544-S545
        • Lawitz E.
        • Lalezari J.P.
        • Hassanein T.
        • et al.
        Once-daily PSI-7977 plus Peg/RBV in treatment-naïve patients with HCV GT1: robust end of treatment response rates are sustained post-treatment (PROTON) (abstr).
        Hepatology. 2011; 54: 472A
        • Chayama K.
        • Takahashi S.
        • Toyota J.
        • et al.
        Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
        Hepatology. 2012; 55: 742-748
        • Lok A.S.
        • Gardiner D.F.
        • Lawitz E.
        • et al.
        Preliminary study of two antiviral agents for hepatitis C genotype 1.
        N Engl J Med. 2012; 366: 216-224
        • Gane E.J.
        • Stedman C.
        • Hyland R.H.
        • et al.
        Once daily PSI-7977 plus RBV: pegylated interferon-alpha not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3 (abstr).
        Hepatology. 2011; 54: 377A
        • Futagawa Y.
        • Terasaki P.I.
        • Waki K.
        • et al.
        No improvement in long-term liver transplant graft survival in the last decade: an analysis of the UNOS data.
        Am J Transplant. 2006; 6: 1398-1406
        • Samuel D.
        • Forns X.
        • Berenguer M.
        • et al.
        Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006).
        J Hepatol. 2006; 45: 127-143

      Supplementary References

        • Pagliaro L.
        • Peri V.
        • Linea C.
        • et al.
        Natural history of chronic hepatitis C.
        Ital J Gastroenterol Hepatol. 1999; 31: 28-44
        • Poynard T.
        • Ratziu V.
        • Charlotte F.
        • et al.
        Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C.
        J Hepatol. 2001; 34: 730-739
        • Serfaty L.
        • Aumaitre H.
        • Chazouilleres O.
        • et al.
        Determinants of outcome of compensated hepatitis C virus-related cirrhosis.
        Hepatology. 1998; 27: 1435-1440
        • Corrao G.
        • Arico S.
        Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis.
        Hepatology. 1998; 27: 914-919
        • Singal A.G.
        • Volk M.L.
        • Jensen D.
        • et al.
        A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus.
        Clin Gastroenterol Hepatol. 2010; 8 (288 e1): 280-288
        • Degos F.
        • Christidis C.
        • Ganne-Carrié N.
        • et al.
        Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.
        Gut. 2000; 47: 131-136
        • D'Amico G.
        • Garcia-Tsao G.
        • Pagliaro L.
        Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.
        J Hepatol. 2006; 44: 217-231
        • El-Serag H.B.
        • Mason A.C.
        • Key C.
        Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States.
        Hepatology. 2001; 33: 62-65
        • El-Serag H.B.
        Hepatocellular carcinoma: recent trends in the United States.
        Gastroenterology. 2004; 127: S27-S34
        • Rossol S.
        Chronic HCV infections.
        Gesundheitswesen. 2007; 69: 146-150
        • Zehnter E.
        • Mauss S.
        • John C.
        • et al.
        Efficacy of peginterferon alfa-2a (40KD) and ribavirin in patients with chronic hepatitis C in Germany—a contribution to health care (abstr).
        Hepatology. 2005; 42: 683A
        • The Hepatitis C Trust
        The UK vs. Europe: losing the fight against hepatitis C.
        University of Southampton, London, England2006
        • Cornberg M.
        • Razavi H.A.
        • Alberti A.
        • et al.
        A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.
        Liver Int. 2011; 31: 30-60
        • Varela M.
        • Reig M.
        • de la Mata M.
        • et al.
        Treatment approach of hepatocellular carcinoma in Spain.
        Med Clin (Barc). 2010; 134: 569-576
        • Bourliere M.
        • Ouzan D.
        • Rosenheim M.
        • et al.
        Efficacy of peginterferon alpha-2a and ribavirin in 2101 patients with HCV infection in real-life clinical practice: results of the French HEPATYS study (abstr).
        Hepatology. 2007; 46: 366A
        • Deuffic S.
        • Buffat L.
        • Poynard T.
        • et al.
        Modeling the hepatitis C virus epidemic in France.
        Hepatology. 1999; 29: 1596-1601
        • Van Vlierberghe H.
        • Colle I.
        • Henrion J.
        • et al.
        The HepCar registry: report on a one-year registration program of hepatocellular carcinoma (HCC) in Belgium.
        Acta Gastroenterol Belg. 2005; 68: 403-411
        • Marcellin P.
        • Pequignot F.
        • Delarocque-Astagneau E.
        • et al.
        Mortality related to chronic hepatitis B and chronic hepatitis C in France: Evidence for the role of HIV coinfection and alcohol consumption.
        J Hepatol. 2008; 48: 200-207
        • Kubicka S.
        • Rudolph K.L.
        • Hanke M.
        • et al.
        Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area.
        Liver. 2000; 20: 312-318
        • Rabe C.
        • Pilz T.
        • Klostermann C.
        • et al.
        Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma.
        World J Gastroenterol. 2001; 7: 208-215
        • Stroffolini T.
        • Andreone P.
        • Andriulli A.
        • et al.
        Characteristics of hepatocellular carcinoma in Italy.
        J Hepatol. 1998; 29: 944-952
        • Stroffolini T.
        • Trevisani F.
        • Pinzello G.
        • et al.
        Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance.
        Dig Liver Dis. 2011; 43: 875-880
        • Mariano A.
        • Scalia Tomba G.
        • Tosti M.E.
        • et al.
        Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy.
        Scand J Infect Dis. 2009; 41: 689-699
      1. Hepatitis C in the UK 2009.
        Health Protection Agency Centre for Infections, London, England2009
        • Marquardt D.
        An algorithm for least-squares estimation of nonlinear parameters.
        J Soc Indust Appl Math. 1963; 11: 431-441
        • Fong K.W.
        • Jefferson T.H.
        • Suyehiro T.
        • et al.
        SLATEC Common Mathematical Library, 1993.
        • Aronsohn A.
        • Ancuta I.
        • Caruntu F.
        • et al.
        Impact of age >65 years on SVR and relapse in chronic hepatitis C (CHC) patients (pts) treated with peginterferon alfa-2a (40KD) (PegIFNα2a[40KD]) plus ribavirin (RBV): Final analysis from the large multinational real-world PROPHESYS cohorts.
        Hepatology. 2011; 54: 836A
        • Stroffolini T.
        • Trevisani F.
        • Pinzello G.B.
        • et al.
        Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance.
        Dig Liver Dis. 2011; 43: 875-880
        • Beutels M.
        • Van Damme P.
        • Aelvoet W.
        • et al.
        Prevalence of hepatitis A, B and C in the Flemish population.
        Eur J Epidemiol. 1997; 13: 275-280
        • Meffre C.
        • Le Strat Y.
        • Delarocque-Astagneau E.
        • et al.
        Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors.
        J Med Virol. 2010; 82: 546-555
        • Thierfelder W.
        • Hellenbrand W.
        • Meisel H.
        • et al.
        Prevalence of markers for hepatitis A, B and C in the German population.
        Eur J Epidemiol. 2001; 17: 429-435
        • Palitzsch K.D.
        • Hottentrager B.
        • Schlottmann K.
        • et al.
        Prevalence of antibodies against hepatitis C virus in the adult German population.
        Eur J Gastroenterol Hepatol. 1999; 11: 1215-1220
        • Ansaldi F.
        • Bruzzone B.
        • Salmaso S.
        • et al.
        Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy.
        J Med Virol. 2005; 76: 327-332
        • Chimeno M.M.
        • Chocarro A.
        • Brezmes P.
        • et al.
        Seroprevalence of hepatitis C virus in the general population [in Spanish].
        Enferm Infecc Microbiol Clin. 2002; 20: 64-67
        • Dominguez A.
        • Bruguera M.
        • Vidal J.
        • et al.
        Community-based seroepidemiological survey of HCV infection in Catalonia, Spain.
        J Med Virol. 2001; 65: 688-693
        • Garcia-Fulgueiras A.
        • Tormo M.J.
        • Rodriguez T.
        • et al.
        Prevalence of hepatitis B and C markers in the south-east of Spain: an unlinked community-based serosurvey of 2,203 adults.
        Scand J Infect Dis. 1996; 28: 17-20
        • Lopez-Izquierdo R.
        • Udaondo M.A.
        • Zarzosa P.
        • et al.
        Seroprevalence of viral hepatitis in a representative general population of an urban public health area in Castilla y Leon (Spain) [in Spanish].
        Enferm Infecc Microbiol Clin. 2007; 25: 317-323
        • Prieto Domingo J.J.
        • Carrion Bolanos J.A.
        • Bandres Moya F.
        Prevalence of hepatitis C virus and excessive consumption of alcohol in a nonhospital worker population [in Spanish].
        Gastroenterol Hepatol. 1997; 20: 479-483
        • Riestra S.
        • Fernandez E.
        • Leiva P.
        • et al.
        Prevalence of hepatitis C virus infection in the general population of northern Spain.
        Eur J Gastroenterol Hepatol. 2001; 13: 477-481
        • Sacristan B.
        • Gastanares M.I.
        • Elena A.
        • et al.
        Seroepidemiologic study of hepatitis C virus infection in a general population from the region of La Rioja, Spain [in Spanish].
        Med Clin (Barc). 1996; 107: 331-335
        • Gungabissoon U.
        • Balogun M.A.
        • Ramsay M.E.
        Hepatitis C virus: laboratory surveillance in England and Wales, 1992-2004.
        Epidemiol Infect. 2007; 135: 541-548
      2. Hepatitis C action plan for Scotland phase II: May 2008 – March 2011.
        The Scottish Government, Edinburgh, Scotland2008
        • Gerard C.
        • Delwaide J.
        • Vaira D.
        • et al.
        Evolution over a 10 year period of the epidemiological profile of 1,726 newly diagnosed HCV patients in Belgium.
        J Med Virol. 2005; 76: 503-510
        • Martinot-Peignoux M.
        • Roudot-Thoraval F.
        • Mendel I.
        • et al.
        Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy.
        The GEMHEP. J Viral Hepat. 1999; 6: 435-443
        • Payan C.
        • Roudot-Thoraval F.
        • Marcellin P.
        • et al.
        Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: the GEMHEP GenoCII Study.
        J Viral Hepat. 2005; 12: 405-413
        • Huppe D.
        • Zehnter E.
        • Mauss S.
        • et al.
        Epidemiology of chronic hepatitis C in Germany—an analysis of 10,326 patients in hepatitis centres and outpatient units [in German].
        Z Gastroenterol. 2008; 46: 34-44
        • Matera G.
        • Lamberti A.
        • Quirino A.
        • et al.
        Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy.
        Diagn Microbiol Infect Dis. 2002; 42: 169-173
        • Serra M.A.
        • Rodriguez F.
        • del Olmo J.A.
        • et al.
        Influence of age and date of infection on distribution of hepatitis C virus genotypes and fibrosis stage.
        J Viral Hepat. 2003; 10: 183-188
        • Echevarria J.M.
        • Leon P.
        • Pozo F.
        • et al.
        Follow-up of the prevalence of hepatitis C virus genotypes in Spain during a nine-year period (1996-2004).
        Enferm Infecc Microbiol Clin. 2006; 24: 20-25
        • Mohsen A.H.
        • Trent HCV Study Group
        The epidemiology of hepatitis C in a UK health regional population of 5.12 million.
        Gut. 2001; 48: 707-713
        • Hutchinson S.J.
        • Roy K.M.
        • Wadd S.
        • et al.
        Hepatitis C virus infection in Scotland: epidemiological review and public health challenges.
        Scott Med J. 2006; 51: 8-15
        • Carsauw H.
        • Adler M.
        • Goubau P.
        • et al.
        Investigations following the use of inactive batch of Cidex solution in Belgian hospitals.
        Acta Gastroenterol Belg. 2003; 66: D35
        • Mariano A.
        • Caserta C.
        • Pendino G.M.
        • et al.
        Antiviral treatment for hepatitis C virus infection: effectiveness at general population level in a highly endemic area.
        Dig Liver Dis. 2009; 41: 509-515
        • Costella A.
        Health Protection Agency United Kingdom. Hepatitis C in the UK 2008. The Health Protection Agency Annual Report.
        Health Protection Agency Centre for Infections, London, England2008
        • Goldberg D.
        • Brown G.
        • Hutchinson S.
        • et al.
        Hepatitis C action plan for Scotland: phase II (May 2008-March 2011).
        Euro Surveill. 2008; 13
      3. Sales Data.
        IMS Health, IMS MIDAS/Q1 20062006
        • Groupement pour l'Elaboration et la Réalisation de Statistiques
        Sales data.
        2006
        • De Maeght S.
        • Henrion J.
        • Bourgeois N.
        • et al.
        A pilot observational survey of hepatitis C in Belgium.
        Acta Gastroenterol Belg. 2008; 71: 4-8
        • Pariente A.
        • Lahmek P.
        • Duprat C.
        • et al.
        Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life': a plea in favor of independent postmarketing evaluations.
        Eur J Gastroenterol Hepatol. 2010; 22: 1297-1302
        • Consell Assessor sobre el tractament farmacologic de les hepatitis viriques
        Informe d'activitats: any 2007.
        (In: Generalitat de Catalunya, Departament de Salut, Direccio General de Recursos Sanitaris) (ed. Barcelona, March 2008.)
        • Pol S.
        • Ghalib R.H.
        • Rustgi V.K.
        • et al.
        First report of SVR12 for a NS5A replication complex inhibitor, BMS-790052 in combination with PEG-IFNα-2a and RBV: Phase 2a trial in treatment-naive HCV-genotype 1 subjects.
        J Hepatol. 2011; 54: S544-S545
        • Lawitz E.
        • Lalezari J.P.
        • Hassanein T.
        • et al.
        Once-daily PSI-7977 plus Peg/RBV in treatment-naïve patients with HCV GT1: robust end of treatment response rates are sustained post-treatment (PROTON) (abstr).
        Hepatology. 2011; 54: 472A
        • Chayama K.
        • Takahashi S.
        • Toyota J.
        • et al.
        Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
        Hepatology. 2012; 55: 742-748
        • Lok A.S.
        • Gardiner D.F.
        • Lawitz E.
        • et al.
        Preliminary study of two antiviral agents for hepatitis C genotype 1.
        N Engl J Med. 2012; 366: 216-224
        • Gane E.J.
        • Stedman C.
        • Hyland R.H.
        • et al.
        Once daily PSI-7977 plus RBV: pegylated interferon-alpha not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3.
        Hepatology. 2011; 54: 377A